Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID

Biotest

Status and phase: Completed; Phase 3

Conditions: Primary Immunodeficiency Disease

Treatments: Biological: IgG Next Generation (BT595)

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT02810444

2015-003652-52 (EudraCT Number)

991

Details and patient eligibility

About

This Phase III clinical study is to test efficacy, safety and pharmacokinetics of BT595 in treating patients with Primary Immunodeficiency (PID)

Enrollment: 81 patients

Sex: All

Ages: 2 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Criteria for inclusion:

1. Written informed consent/assent obtained from subjects/subjects' parent(s) or legally acceptable representative indicating that they understood the purpose of, and procedures required for the study and are willing to participate in it.

2. Male or female, aged 2 through 75 years, inclusive.

3. Diagnosis of PID with impaired antibody production, ie:

   • Diagnosis of common variable immunodeficiency (CVID) as defined by the European Society for Immunodeficiencies (ESID)/Pan American Group for Immunodeficiency (PAGID) diagnostic criteria.

   Or

   • X-linked agammaglobulinaemia (XLA) as defined by ESID/PAGID diagnostic criteria.

4. Established replacement therapy with any immunoglobulin for intravenous administration (IVIg) reference preparation during the previous 6 months, including documentation of IgG trough levels.

5. Established replacement therapy with a single IVIg reference preparation for ≥3 months prior to treatment start with BT595 at a 3 week (Q3W) or 4 week (Q4W) schedule with a constant IVIg dose that did not change by ±20% of the mean dose, regular dosage intervals, and at least 1 IgG trough level of ≥5 g/L during the previous 3 months.

Criteria for exclusion:

1. Pregnancy or unreliable contraceptive measures or lactation period (females only).
2. Known intolerance to immunoglobulins or comparable substances (eg, vaccination reaction).
3. Known intolerance to proteins of human origin or known allergic reactions to components of the study product.
4. Participation in another clinical study within 30 days before entering the study or during the study and/or previous participation in this study.
5. Employee or direct relative of an employee of the contract research organization, the study site, or Biotest.
6. Acquired medical conditions known to cause secondary immune deficiency, such as chronic lymphatic leukemia, lymphoma, multiple myeloma, as well as protein losing enteropathies and hypoalbuminemia.
7. Other medical condition, laboratory finding, or physical examination finding that precludes participation.
8. Recent febrile illness that precludes or delays participation.
9. Active infection and receiving antibiotic therapy for the treatment of this infection at the time of screening. Note: if the subject was deemed to be a screen failure due to a nonserious active infection requiring antibiotic therapy, the subject may have been rescreened after the initial screening.
10. Therapy with systemic steroids or other immunosuppressant drugs at the time of enrollment (current daily use of corticosteroids, ie, >10 mg prednisone equivalent/day for >30 days. Intermittent corticosteroid use during the study was allowable, if medically necessary).
11. History of thrombotic events (including myocardial infarction, cerebral vascular accident [including stroke], pulmonary embolism, and deep vein thrombosis) within the 6 months before treatment start with BT595 or the presence of significant risk factors for thrombotic events.
12. Therapy with live-attenuated virus vaccines within 3 months before start of the study.
13. Selective, absolute immunoglobulin A (IgA) deficiency or known antibodies to IgA.
14. Positive diagnosis of hepatitis B or hepatitis C.
15. Positive human immunodeficiency virus (HIV) test.
16. History of drug or alcohol abuse within the 12 months before treatment start with BT595.
17. Inability or lacking motivation to participate in the study.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

81 participants in 1 patient group

BT595

Experimental group

Description:

Subjects received BT595 (100 mg/mL human normal immunoglobulin) at doses between 0.2 and 0.8 g per kg body weight (bw) (2 to 8 mL/kg bw), either at a Q3W or Q4W schedule, The initial doses and dosage interval had to be consistent with the subject's prestudy IVIg treatment.

Treatment:

Biological: IgG Next Generation (BT595)